Herceptin HYLECTA: What it treats Adjuvant Breast Cancer. HERCEPTIN HYLECTA (trastuzumab and hyaluronidase-oysk) is approved for the treatment of adults with early-stage breast cancer that is Human Epidermal growth factor Receptor 2-positive (HER2+) and has spread into the lymph nodes, or is HER2-positive and has not spread into the lymph nodes ...

Read about the treatment schedule for Herceptin® (trastuzumab), a treatment for HER2+ early breast cancer. See Full Safety and Boxed Warnings for more information. For US Healthcare Professionals

Learn about potential side effects when using Herceptin® (trastuzumab) as a HER2+ metastatic breast cancer treatment. Read the Important Safety Information (ISI) for Herceptin® (trastuzumab). See full safety & Boxed Warnings for more information.

Herceptin HYLECTA: What it treats Adjuvant Breast Cancer. HERCEPTIN HYLECTA (trastuzumab and hyaluronidase-oysk) is approved for the treatment of adults with early-stage breast cancer that is Human Epidermal growth factor Receptor 2-positive (HER2+) and has spread into the lymph nodes, or is HER2-positive and has not spread into the lymph nodes ...

Herceptin HYLECTA: What it treats Adjuvant Breast Cancer. HERCEPTIN HYLECTA (trastuzumab and hyaluronidase-oysk) is approved for the treatment of adults with early-stage breast cancer that is Human Epidermal growth factor Receptor 2-positive (HER2+) and has spread into the lymph nodes, or is HER2-positive and has not spread into the lymph nodes ...

What to expect with Herceptin® (trastuzumab), a treatment for HER2+ early breast cancer including monitoring potential side effects, heart monitoring and testing during treatment. See full safety & Boxed Warnings for more information.

Herceptin administration can result in serious and fatal infusion reactions; Symptoms usually occur during or within 24 hours of Herceptin administration; Interrupt Herceptin infusion for dyspnea or clinically significant hypotension; Monitor patients until symptoms completely resolve

One week following the last weekly dose of Herceptin, administer Herceptin at 6 mg/kg as an intravenous infusion over 30-90 minutes every three weeks As a single agent within three weeks following completion of multi-modality, anthracycline-based chemotherapy regimens:

Herceptin HYLECTA: What it treats Adjuvant Breast Cancer. HERCEPTIN HYLECTA (trastuzumab and hyaluronidase-oysk) is approved for the treatment of adults with early-stage breast cancer that is Human Epidermal growth factor Receptor 2-positive (HER2+) and has spread into the lymph nodes, or is HER2-positive and has not spread into the lymph nodes ...

Learn about potential side effects when using Herceptin® (trastuzumab) as a HER2+ early breast cancer treatment. Read the Important Safety Information (ISI) for Herceptin® (trastuzumab). See full safety & Boxed Warnings for more information.